JP2024522360A - 抗ｃｃｒ８抗体及びその使用 - Google Patents

抗ｃｃｒ８抗体及びその使用 Download PDF

Info

Publication number
JP2024522360A
JP2024522360A JP2023574361A JP2023574361A JP2024522360A JP 2024522360 A JP2024522360 A JP 2024522360A JP 2023574361 A JP2023574361 A JP 2023574361A JP 2023574361 A JP2023574361 A JP 2023574361A JP 2024522360 A JP2024522360 A JP 2024522360A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
ccr8
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522360A5 (enExample
Inventor
ウィリアム ピアース，ネイサン
キェチェウスカ，アグニエシュカ
チェン，ウェンタオ
ノーラン－ステヴォー，オリヴィエ
エル． ベイツ，ダレン
ウィンケル，リサ
ダールホフ，クリストフ
ラウム，トビアス
ブルーメル，クラウディア
カール－ヨーゼフ ホーナー，ヨナス
Original Assignee
アムジエン・インコーポレーテツド
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド, アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical アムジエン・インコーポレーテツド
Publication of JP2024522360A publication Critical patent/JP2024522360A/ja
Publication of JP2024522360A5 publication Critical patent/JP2024522360A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023574361A 2021-06-04 2022-06-02 抗ｃｃｒ８抗体及びその使用 Pending JP2024522360A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163197271P 2021-06-04 2021-06-04
US63/197,271 2021-06-04
US202163236551P 2021-08-24 2021-08-24
US63/236,551 2021-08-24
PCT/US2022/032011 WO2022256563A1 (en) 2021-06-04 2022-06-02 Anti-ccr8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024522360A true JP2024522360A (ja) 2024-06-18
JP2024522360A5 JP2024522360A5 (enExample) 2025-06-11

Family

ID=82358418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574361A Pending JP2024522360A (ja) 2021-06-04 2022-06-02 抗ｃｃｒ８抗体及びその使用

Country Status (17)

Country Link
US (2) US12258411B2 (enExample)
EP (1) EP4347655A1 (enExample)
JP (1) JP2024522360A (enExample)
KR (1) KR20240017912A (enExample)
AU (1) AU2022285741A1 (enExample)
BR (1) BR112023025433A2 (enExample)
CA (1) CA3222764A1 (enExample)
CL (2) CL2023003607A1 (enExample)
CO (1) CO2023018064A2 (enExample)
CR (1) CR20230581A (enExample)
IL (1) IL308808A (enExample)
JO (1) JOP20230312A1 (enExample)
MX (1) MX2023014458A (enExample)
PE (1) PE20240363A1 (enExample)
TW (1) TW202313684A (enExample)
UY (1) UY39798A (enExample)
WO (1) WO2022256563A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022285741A1 (en) * 2021-06-04 2023-12-14 Amgen Inc. Anti-ccr8 antibodies and uses thereof
US20240165227A1 (en) * 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2007044756A2 (en) 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CN110835371A (zh) 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
AU2021205877B2 (en) * 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
JP7859975B2 (ja) 2020-06-30 2026-05-15 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Ｃｃｒ８抗体及びその用途
EP4228764A1 (en) * 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
IL308809A (en) * 2021-06-04 2024-01-01 Amgen Res Munich Gmbh T cell binding compounds and their uses
AU2022285741A1 (en) * 2021-06-04 2023-12-14 Amgen Inc. Anti-ccr8 antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
WO2020138489A1 (ja) * 2018-12-27 2020-07-02 塩野義製薬株式会社 新規抗ｃｃｒ８抗体

Also Published As

Publication number Publication date
CL2024003552A1 (es) 2025-08-01
EP4347655A1 (en) 2024-04-10
CL2023003607A1 (es) 2024-06-07
AU2022285741A1 (en) 2023-12-14
CO2023018064A2 (es) 2024-01-15
BR112023025433A2 (pt) 2024-02-27
US12258411B2 (en) 2025-03-25
KR20240017912A (ko) 2024-02-08
WO2022256563A1 (en) 2022-12-08
UY39798A (es) 2022-12-30
MX2023014458A (es) 2023-12-15
TW202313684A (zh) 2023-04-01
PE20240363A1 (es) 2024-03-04
US20250171549A1 (en) 2025-05-29
IL308808A (en) 2024-01-01
CR20230581A (es) 2024-02-13
JOP20230312A1 (ar) 2023-11-29
CA3222764A1 (en) 2022-12-08
US20220403037A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
CN112513080B (zh) Vista抗原结合分子
JP7287963B2 (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
CN112566935B (zh) 抗ox40抗体和使用方法
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
CN110536903B (zh) 抗ox40抗体及其用途
US11008391B2 (en) Anti-PD-1 antibodies
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
JP7727086B2 (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
US20230279130A1 (en) Anti-ccr8 antibodies
JP2018523652A (ja) Ｐｄ−１アンタゴニストとｅｇｆｒ阻害剤の組み合わせ物
US20240309087A1 (en) Anti-cd112r antibody and use thereof
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2025041695A (ja) 抗体および使用方法
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
JP2024530467A (ja) ヒトインターロイキン－４受容体アルファ抗体
WO2023036281A1 (zh) 抗cd47抗体及其用途
US20230272067A1 (en) Human monoclonal antibodies against tigit for immune related diseases
JP2025525916A (ja) 抗ｃｃｒ８抗体及び使用方法
CN114057876A (zh) Cd47抗体及其应用
CN121079322A (zh) 抗cd27单克隆抗体及其应用
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
IL281767B2 (en) Antibodies directed against CD137 and methods of using them
CN117858899A (zh) 抗ccr8抗体及其用途
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807